ADC Therapeutics (ADCT) Change in Account Payables (2020 - 2026)

ADC Therapeutics (ADCT) has reported Change in Account Payables for 7 consecutive years, with -$3.9 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Account Payables fell 57.42% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 937.42% YoY) and the FY2025 annual result came in at -$9.0 million, down 467.1% from the prior year.
• Change in Account Payables retreated to -$3.9 million in Q1 2026 per ADCT's latest filing, from $932000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for ADCT reached as high as $6.6 million in Q4 2023 and fell as low as -$6.2 million in Q2 2025.
• A 5-year average of -$409823.5 and a median of -$1.3 million in 2025 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables jumped 811.37% — and 2024, when it sank 262.5%.
• Year by year, Change in Account Payables stood at $721000.0 in 2022, then soared by 811.37% to $6.6 million in 2023, then slumped by 44.01% to $3.7 million in 2024, then tumbled by 74.67% to $932000.0 in 2025, then slumped by 515.67% to -$3.9 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$3.9 million, $932000.0, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.